Christopher Hill

Exceptional activity for NO x reduction at low temperatures using combinations of hydrogen and higher hydrocarbons on Ag/Al2O3 catalysts

R. Burch, John P. Breen, Christopher Hill et al. · Topics in Catalysis · 2004 · 119 citations

Natural Sciences, Chemistry, Materials Science +16

Impact of primary kidney disease on the effects of empagliflozin in patients with chronic kidney disease: secondary analyses of the EMPA-KIDNEY trial

PK Judge, Natalie Staplin, KJ Mayne et al. · The Lancet Diabetes & Endocrinology · 2023 · 108 citations · Full text

Medicine, Nephrology, Pharmacotherapy +11

An in situ UV–vis and FTIR spectroscopy study of the effect of H and CO during the selective catalytic reduction of nitrogen oxides over a silver alumina catalyst

Blanka Wichterlová, Petr Sazama, John M. Breen et al. · Journal of Catalysis · 2005 · 95 citations

Natural Sciences, Chemical Engineering, Chemistry +17

Chronic kidney disease and diabetes in the National Health Service: a cross‐sectional survey of the UK National Diabetes Audit

Christopher Hill, Chris R. Cardwell, C. C. Patterson et al. · Diabetic Medicine · 2013 · 90 citations · Full text

Medicine, Internal Medicine, Nephrology +17

Effects of empagliflozin on progression of chronic kidney disease: a prespecified secondary analysis from the empa-kidney trial

Natalie Staplin, Richard Haynes, PK Judge et al. · The Lancet Diabetes & Endocrinology · 2023 · 90 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +14